Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2018 ( 7 )

2017 ( 4 )

2016 ( 9 )

2015 ( 147 )

Custom range...

Search Results: 1 - 10 of 3029 matches for " Giorgio Dalla Volta "
All listed articles are free for downloading (OA Articles)
Page 1 /3029
Display every page Item
A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study  [PDF]
Paola Zavarise, Giorgio Dalla Volta
Open Access Library Journal (OALib Journal) , 2017, DOI: 10.4236/oalib.1103660
Background: effective treatments for migraine aura and related symptoms are not yet well established. In the last years, several herbal and/or nutraceutical preparations have been proposed as potential treatment. We report the results of a retrospective analysis on the synergistic effect of three nutraceutical components (Tanacetum parthenium, Griffonia simpliciofila and Magnesium, Aurastop) as symptomatic treatment of migraine aura and related symptoms. Method: Forty-nine subjects with headache with aura were recruited from the headache Center of the Istituto Clinico Citta’ di Brescia to enter the studied that consist to treat the first 3 aura attacks as usual and the next 3 taking a tablet of Aurastop at the beginning of the aura phenomena. They had to describe aura and headache characteristics of previous three attacks (t1) and the modification of these parameters with the assumption of Aurastop for the following three attacks (t2). Results: A significant reduction (>50%) in aura duration (t1 = 33.6 ± 10.1 minutes vs. t2 = 9.4 ± 6.2 minutes, p < 0.01 FWER corrected) as well as in overall disability (median [interquartile range]) (t1 = 5[4 - 5] vs. t2 = 1[1 - 2], p < 0.01 FWER corrected) was evident. Furthermore, modification of aura type as well as a series of parameters more related to headache (number of headache attacks, duration, intensity, utilization of analgesics and response to symptomatic treatment) was influenced by Aurastop utilization (p < 0.01 FWER corrected). No significant adverse effects were recorded after the assumption of Aurastop. Conclusions: the combined and synergistic effect of Tanacetum parthenium, Griffonia simpliciofila and Magnesium (Aurastop) highlights the idea that symptomatic treatment potentially modulating cortical spreading depression could deserve attention to mitigate aura and related symptoms (migraine as well as long-lasting discomfort). Further blinded, placebo-controlled studies on larger groups are warranted.
Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in the Prevention of High Frequency Migraine with Aura  [PDF]
Giorgio Dalla Volta, Paola Zavarise, Laura Perego, Alessandro Pezzini
Open Access Library Journal (OALib Journal) , 2018, DOI: 10.4236/oalib.1104939
Object: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop) in the prophylactic treatment of high frequency migraine with aura (MWA). According to the international headache classification (IHCD 3 beta version) the aura phenomena have a duration of 5 - 60 minutes for any of the usual disturbances (visual, somatosensory and speech disturbance) but no classification describes the frequency of this phenomena. Patients who experience migraine aura emphasize the emotional impact of such a phenomenon, mostly because of the severe, though transient, disability caused by the aura symptoms (i.e., inability to work or driving a vehicle). Furthermore, a profound asthenia lasts for about 48 hours after the resolution of the painful phase. Materials and Method: 18 patients (F: n = 10, M: n = 8, mean age: 28) presenting with an ICHD-3 beta diagnosis of migraine with aura (MWA) with a frequency of more than 5 attacks of migraine with aura per month since at least 6 months, were enrolled in the survey and treated with Aurastop© twice a day for a period of 3 months. Diary cards were filled in during a 3-month period before the beginning of the survey and during the 3-month duration of the study. The reduction of MWA attacks per month was assessed as the primary end-point; the reduction of the duration and disability of the aura and of the intensity of the headache were considered as secondary end-points. Results: A statistically significant reduction of MWA attacks/month was observed: more than 95% of the patients referred a reduction >50% of the frequency, 66.6% a reduction of more than 70%, and 16.6% a complete disappearance of the attacks after the first week of therapy. Moreover, a sensible reduction of the duration and disability of the aura phenomena was reported by more than 90% of the patients and, in the 55% of the patients also a reduction of the intensity of the headache. No side effects were reported. The efficacy started to appear during the first month of intake and was maintained during the three months of therapy.
Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop) in Episodic Migraine Prevention: A Multicentric Observational Study  [PDF]
Federico Mainardi, Paola Merlo, Ferdinando Maggioni, Giorgio Zanchin, Giorgio Dalla Volta
Open Access Library Journal (OALib Journal) , 2018, DOI: 10.4236/oalib.1104765
Objective: To verify the efficacy and safety of the new combination of Tanacetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and magnesium 185 mg (Aurastop) in the prophylactic treatment of episodic migraine without aura (MO). Methods: Eighty patients suffering from MO for at least 6 months with a monthly frequency of 3 to 8 attacks and 4 to12 headache days, were enrolled in this open study and treated with Aurastop twice daily per os for 3 months. The reduction of headache days per month was assessed as the primary end-point, while the secondary end-points were: 1) reduction of the number of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drug intake; 4) subjective change of pain intensity. Results: All the parameters significantly improved at the end of the observational period of treatment with Aurastop. In more detail: a significant reduction of the number of headache days (from 9.1 ± 2.0 before treatment to 3.2 ± 1.8 post treatment, p < 0.001); number of attacks per month (from 6.0 ± 1.2 to 2.4 ± 1.1, p < 0.001); pain intensity (in a visual analogical scale [VAS]: from 7 ± 1.0 to 3.2 ± 0.7, p < 0.001); number of drug doses for acute treatment (triptans, simple analgesics or in combination) assumed by each subject per month (from 9.5 ± 1.8 to 2.2 ± 1.1, p < 0.001). No serious adverse events were observed. Conclusion: Albeit obtained with the limitation of open-trials, our findings suggest that AURASTOP is a promising approach for migraine prevention; further investigations are required to confirm the safety and efficacy of this treatment.
The Migraine-Ischemic Stroke Relation in Young Adults
Alessandro Pezzini,Elisabetta Del Zotto,Alessia Giossi,Irene Volonghi,Paolo Costa,Giorgio Dalla Volta,Alessandro Padovani
Stroke Research and Treatment , 2011, DOI: 10.4061/2011/304921
Abstract: In spite of the strong epidemiologic evidence linking migraine and ischemic stroke in young adults, the mechanisms explaining this association remain poorly understood. The observation that stroke occurs more frequently during the interictal phase of migraine prompts to speculation that an indirect relation between the two diseases might exist. In this regard, four major issues might be considered which may be summarized as follows: (1) the migraine-ischemic stroke relation is influenced by specific risk factors such as patent foramen ovale or endothelial dysfunction and more frequent in particular conditions like spontaneous cervical artery dissection; (2) migraine is associated with an increased prevalence of cardiovascular risk factors; (3) the link is caused by migraine-specific drugs; (4) migraine and ischemic vascular events are linked via a genetic component. In the present paper, we will review epidemiological studies, discuss potential mechanisms of migraine-induced stroke and comorbid ischemic stroke, and pose new research questions. 1. Introduction Migraine affects about 15% of people in developed countries [1] and is three times more common in women than in men. Patients have a median of one attack per month, and 25% have at least two attacks per month [2]. Patients with more than one attack per month are at increased risk of brain lesions [3]. In the last decades, several studies have emphasized the high prevalence of migraine among young individuals with stroke as well as a dysfunction of cerebral arteries during migraine attacks and the finding of silent infarct-like brain lesions in migraineurs, thus leading to the hypothesis that a comorbidity between migraine and cerebral ischemia exists [4]. 2. Evidence of Association The first epidemiological suggestion that migraine may be an independent risk factor for stroke came from the Collaborative Group for the Study of Stroke in Young Women, published in 1975, which showed an increased relative risk of stroke with migraine compared with neighbor controls [5]. Since then, the association of migraine with the risk of stroke has been investigated in several observational studies, most of which have been summarized in a recent meta-analysis [6]. According to this meta-analysis, the pooled relative risk of ischemic stroke among patients with any type of migraine is 1.73 (95% CI, 1.31 to 2.29). The relative risk for women is increased (RR 2.08, 95% CI 1.13 to 3.84) but not for men (RR 1.37, 95% CI 0.89 to 2.11). Stratifying analysis by age, people with migraine aged less than 45 have an higher
New Therapeutic Approach to Primary Stabbing Headache  [PDF]
Gaelle K. Ngonga, Daniela Carli, Paola Zavarise, Stefano Vollaro, Giorgio Dalla Volta
Open Access Library Journal (OALib Journal) , 2016, DOI: 10.4236/oalib.1102529
Abstract: Primary stabbing headache has been known for several decades. However, the pathophysiology of this disease is not still understood. It is clinically characterized by single episodes or short-lasting series of stabbing pain recurring from once to many times per day in an irregular pattern. The diagnosis is clinical and any other possible cause should be excluded. The therapeutic approach indicates Indomethacin as the first choice of treatment, although case reports describe a therapeutic response to Melatonin, Celecoxib, Nidedipine, Paracetamol and Gabapentin. We describe the case of 5 patients with diagnosis of primary stabbing headache without comorbidity of anxiety or depression that shows a partial response to Indomethacin, but do respond to Benzodiazepines. There is little on the use of Benzodiazepines in primary headaches. They are used in patients with chronic migraine when there is a comorbidity of anxiety and depression. The unexpected efficacy of these molecules in our patients is encouraging and represents a hint to think about using these molecules in other types of primary headaches.
Sergio DallaVolta, MD, PhD
European Journal of Cardiovascular Medicine , 2010,
Abstract: n the last fifteen years much progress has been made on the knowledge of the mechanisms controlling the genetic and molecular activities of the mammalian (with special emphasis on the human) heart in chronic cardiac insufficiency.This increased knowledge has greatly influenced the understanding and treatment of heart failure, helping to prolong duration of life; even if clear evidence of a long lasting improvement of the syndrome is lacking.The causes of heart failure are numerous and different, but the common feature depends on the modest regenerative capacity of the human heart after any important injury damaging the myocardium. Therefore, the more frequent consequence is the appearance of scar tissue, with collagen deposition and tissue remodelling. Even is some proliferation of cardiac myocites has been noted, this process is unable to overcome the destruction of normal cells observed in the several cardiac disorders, so that the only efficient response is usually the cellular hypertrophy.
On Orbit Equivalence and Permutation groups defined by unordered relations
F. Dalla Volta,J. Siemons
Mathematics , 2010,
Abstract: For a set $\Omega$ an unordered relation on $\Omega$ is a family R of subsets of $\Omega.$ If R is such a relation we let G(R) be the group of all permutations on $\Omega$ that preserves R, that is g belongs to G(R) if and only if x in R implies x^{g}\in R. We are interested in permutation groups which can be represented as G=G(R) for a suitable unordered relation R on $\Omega.$ When this is the case, we say that G is defined by the relation R, or that G is a relation group. We prove that a primitive permutation group different from the Alternating Group and of degree bigger or equal to 11 is a relation groups. The same is true for many classes of finite imprimitive groups, and we give general conditions on the size of blocks of imprmitivity, and the groups induced on such blocks, which guarantee that the group is defined by a relation. This property is closely connected to the orbit closure of permutation groups. Since relation groups are orbit closed the results here imply that many classes of imprimitive permutation groups are orbit closed.
On solvable minimally transitive permutation groups
Francesca Dalla Volta,Johannes Siemons
Mathematics , 2007,
Abstract: We investigate properties of finite transitive permutation groups $(G, \Omega)$ in which all proper subgroups of $G$ act intransitively on $\Omega.$ In particular, we are interested in reduction theorems for minimally transitive representations of solvable groups.
Abelian regular subgroups of the affine group and radical rings
A. Caranti,Francesca Dalla Volta,Massimiliano Sala
Mathematics , 2005,
Abstract: We establish a link between abelian regular subgroup of the affine group, and commutative, associative algebra structures on the underlying vector space that are (Jacobson) radical rings. As an application, we show that if the underlying field has positive characteristic, then an abelian regular subgroup has finite exponent if the vector space is finite-dimensional, while it can be torsion free if the dimension is infinite. We also give an example of an abelian, regular subgroup of the affine group over an infinite vector space, which intersects trivially the group of translations.
An application of the O'Nan-Scott theorem to the group generated by the round functions of an AES-like cipher
A. Caranti,F. Dalla Volta,M. Sala
Mathematics , 2008,
Abstract: In a previous paper, we had proved that the permutation group generated by the round functions of an AES-like cipher is primitive. Here we apply the O'Nan Scott classification of primitive groups to prove that this group is the alternating group.
Page 1 /3029
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.